About
Telo Therapeutics develops orally bioavailable targeted protein degraders that inhibit nuclear transport proteins like XPO1, aiming to treat solid and hematological cancers that are resistant to existing therapies.
Explore Telo Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.